Abstract Body

Background

Characterization of HIV humoral immunity has provided insights into the role of HIV antibodies (Ab) in controlling HIV and as biomarkers of HIV replication during infection and antiretroviral therapy (ART) use. The aim of this study was to determine if HIV Ab and antigen (Ag) quantitation could detect anamnestic induction of humoral immunity prior to detectable plasma viral load (VL) rebound following analytical treatment interruption (ATI), and if longitudinal measurements of p24 Ag/Ab provide insights into post-rebound viral replication. 

Methods

Longitudinal plasma samples from 41 ACTG A5345 study participants who started ART during chronic or early phase of infection and underwent ATI (88% males, 485 samples; mean 12/participant), previously characterized for plasma VL rebound kinetics and virological correlates of time to rebound, were analyzed using the Ortho Vitros HIV1+2 (p24/env Ab) and Combo (p24 Ag/env Ab), the Sedia Limiting Ag Avidity and the Bio-Rad BioPlex2200 HIV Ag-Ab (p24 Ag/HIV M/O/2 Ab)assays which discriminates p24 Ag and Ab signals, with and without a denaturation step to separate p24 Ag-Ab immune complexes (IC).

Results

Neither Ab nor Ag increased prior to VL rebound. 31 of 41 (76%) participants (both chronic and early treated) showed increased Ab levels (2 timepoints >10% from baseline) following RNA rebound peak and declined after restarting ART. The 8 participants who did not show increased seroreactivity had higher Ab levels at ATI initiation (mean Ortho Combo S/CO 237 vs 154, p<0.001 one-way ANOVA). Early-treated participants had lower Ab levels at ATI initiation (early vs chronic-treated S/CO 80 vs 173, p=0.0004), but larger fold increases during ATI (1.6 vs 1.2-fold, p=0.002) (Fig.1). Two participants with post-treatment control had progressive increase in seroreactivity that paralleled the slow/intermittent increases in VL. p24 Ag was not detectable without the denaturation step; however, after IC dissociation, p24 Ag reactivity became positive in samples with VL >104 RNA copies/mL and correlated with the VL levels across the longitudinal series (Spearman r=0.89). 

Conclusions

Commercial HIV serological assays detected an anamnestic Ab induction following VL rebound after ATI in 76% of cases. p24 Ag was detectable at rebound VL>104 RNA copies/mL only following IC dissociation.  Longitudinal p24 Ag/Ab quantitation provides insights into post-rebound viral replication and impact of ART reinitiation and could be useful for monitoring of ATIs.   

Table or Figure